Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients-a systematic review

Transplantation Reviews

Volumn 23, Issue 3, 2009, Pages 171-177

  Zuk, Dalyce M ^a   Pearson, Glen J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; EVIDENCE BASED MEDICINE; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDLINE; SYSTEMATIC REVIEW;

EID: 67349163207     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2009.02.002     Document Type: Article

References (23)

1. Ross H., Hendry P., Dipchand A., et al. 2001 Canadian cardiovascular society consensus conference on cardiac transplantation. Can J Cardiol 19 (2003) 1-35
2. Lindenfeld J., Miller G.G., Shakar S.F., et al. Drug therapy in the heart transplant recipient-Part II: immunosuppressive drugs. Circulation 110 (2004) 3858-3865
3. Mueller X.M. Drug immunosuppression therapy for adult heart transplantation-Part 1: immune response to allograft and mechanism of action of immunosuppressants. Ann Thorac Surg 77 (2004) 354-362
4. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. JHLT 25 (2006) 869-879
5. Pethig K., Heublein B., Wahlers T., et al. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. JHLT 23 (2004) 61-66
6. Weigel G., Griesmacher A., Kirimi A., et al. Effect of mycopheonate mofetil therapy on lymphocyte activation in heart transplant recipients. JHLT 21 (2002) 1074-1079
7. Lietz K., John R., Schuster M., et al. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients. Transplant Proc 34 (2002) 1828-1829
8. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66 (1998) 507-515
9. Shaw L.M., Holt D.W., Oellerich M., et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23 (2001) 305-315
10. van Hest R.M., Mathot R.A., Vulto A.G., et al. Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. Ther Drug Monit 28 (2006) 31-34
11. Shum B., Duffull S.B., Taylor P.J., et al. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 56 (2003) 188-197
12. Hesse C.J., Vantrimpont P., van Riemsdijk-van Overbeeke I.C., et al. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. Transplant Proc 33 (2001) 2163-2164
13. U.S. Preventive Services Task Force: guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. (1996), Williams & Wilkins, Baltimore 861
14. DeNofrio D., Loh E., Kao A., et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 19 (2000) 1071-1076
15. Cantin B., Giannetti N., Parekh H., et al. Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant 16 (2002) 196-201
16. Gajarski R.J., Crowley D.C., Zamberian M.C., et al. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter?. Am J Transplant 4 (2004) 1495-1500
17. Wada K., Takada M., Kotake T., et al. Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients-comparison of cyclosporine and tacrolimus treatment. Circulation 71 (2007) 1022-1028
18. Meiser B.M., Pfeiffer M., Schmidt D., et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. JHLT 18 (1999) 143-149
19. Yamani M.H., Starling R.C., Goormastic M., et al. Impact of routine mycophenolate monitoring on the treatment of cardiac allograft rejection. Transplantation 69 (2000) 2326-2330
20. Schutz E., Shipkova M., Armstrong V.W., et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 30 (1998) 1185-1187
21. Shipkova M., Schutz E., Armstrong V.W., et al. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc 31 (1999) 1135-1137
22. Pawinski T., Hale M., Korecka M., et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with tacrolimus. Clin Chem 48 (2002) 1497-1504
23. Baraldo M., Isola M.T., Feruglio A., et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic hearth transplant patients. Transplant Proc 37 (2005) 2240-2243